

TECHNICAL NOTE

Comparison between Bioanalyzer and Fragment Analyzer Traces for QC of Chromium™ Genome v2 Libraries

INTRODUCTION

Preparation of Chromium™ Genome v2 libraries follows a protocol that includes DNA extraction/ quantitation, GEM preparation, amplification and size selection followed by the actual library construction. Within the workflow are points where the success of the procedure may be monitored. This Technical Note highlights the usage of Bioanalyzer and Fragment Analyzer traces as a form of QC after library preparation with a focused discussion on evaluation of insert sizes.

METHODS AND RESULTS

The current method for qualitative evaluation of Chromium Genome libraries is through 1) qualitative analysis with either the Agilent Bioanalyzer DNA1000 chip, the Agilent TapeStation D1000 ScreenTape chip, or the Advanced Analytical Fragment Analyzer DNF-474 HS NGS kit and 2) quantification by qPCR. Four Chromium Genome v2 libraries were generated using human gDNA purified with the QIAGEN® MagAttract® HMW Kit per the protocol in the *Chromium™ Genome Reagent Kits v2 User Guide* – CG00043. For QC of the final Genome v2 library, 1 µl of each of the four libraries is used on either the Bioanalyzer or Fragment Analyzer. The traces in Figure 1 are from the four different libraries, each analyzed on both the Bioanalyzer and the Fragment Analyzer and illustrate the differences in fragment size distribution for each instrument. The Bioanalyzer and the Fragment Analyzer use different gel matrices and physical methods of separation that influence both resolution and sensitivity throughout the dynamic range of analysis. As a result, the shape of electropherogram curves, peak maxima, peak number, fluorescent units on the y-axis, and average size will differ slightly between the two instruments. For instance, Library #2 indicates a peak ~650bp on the Bioanalyzer while the same library peaks at ~700bp on the Fragment Analyzer.




Fig. 1. Chromium™ Genome v2 libraries run on an Agilent Bioanalyzer DNA1000 chip (left) and a Fragment Analyzer DNF-474 High Sensitivity NGS Analysis kit (right) for direct comparison.

All traces in this Technical Note are typical of Chromium Genome v2 libraries and were generated using the protocol in the *Chromium™ Genome Reagent Kits v2 User Guide – CG00043*. Importantly, all of these libraries generated successful sequencing results. Therefore, the shape and absolute bp size of the peaks in the traces are not correlated with sequencing success and overall application performance. In general, we look for traces that have a significant proportion of inserts in the 400 bp – 600 bp range, similar to what is seen in the examples in Figure 1. Inserts in this size range are optimal for cluster formation on Illumina® flow cells. If the peak of the fragment distribution curve on the Bioanalyzer or Fragment Analyzer electropherogram is between 400 bp to 1000 bp and the curve distribution indicates the presence of inserts from 400 bp to 600 bp in size, we encourage the User to sequence the sample. The presence of larger fragments does not affect application performance.

DISCUSSION

This Technical Note highlights the differences in fragment size distribution lengths observed when the same libraries are run on both the Bioanalyzer and the Fragment Analyzer. Curve shapes and peak values of library traces are to be used as a quality measure prior to library quantitation and sequencing. The examples of four individual libraries presented here serve as a general guideline to compare with other libraries generated with the Chromium™ Reagent Kits v2.

REFERENCES

- *Chromium™ Genome Reagent Kits v2 User Guide (CG00043)*

Notices

Document Number

CG000117 Rev A *Technical Note*

Legal Notices

© 2017 10x Genomics, Inc. All rights reserved. Duplication and/or reproduction of all or any portion of this document without the express written consent of 10x Genomics, Inc., is strictly forbidden. Nothing contained herein shall constitute any warranty, express or implied, as to the performance of any products described herein. Any and all warranties applicable to any products are set forth in the applicable terms and conditions of sale accompanying the purchase of such product. 10x Genomics provides no warranty and hereby disclaims any and all warranties as to the use of any third party products or protocols described herein. The use of products described herein is subject to certain restrictions as set forth in the applicable terms and conditions of sale accompanying the purchase of such product. "10x", "10x Genomics", "Changing the Definition of Sequencing", "Chromium", "GemCode", "Loupe", "Long Ranger", "Cell Ranger" and "Supernova" are trademarks of 10x Genomics, Inc. All other trademarks are the property of their respective owners. All products and services described herein are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.

The use of 10x Product(s) in practicing the methods set forth herein has not been validated by 10x, and such non-validated use is NOT COVERED BY 10X STANDARD WARRANTY, AND 10X HEREBY DISCLAIMS ANY AND ALL WARRANTIES FOR SUCH USE.

Nothing in this document should be construed as altering, waiving or amending in any manner 10x Genomics, Inc., terms and conditions of sale for the Chromium™ Controller, consumables or software, including without limitation such terms and conditions relating to certain use restrictions, limited license, warranty and limitation of liability, and nothing in this document shall be deemed to be Documentation, as that term is set forth in such terms and conditions of sale. Nothing in this document shall be construed as any representation by 10x Genomics, Inc that it currently or will at any time in the future offer or in any way support any application set forth herein.

Customer Information and Feedback

For technical information or advice, please contact our Customer Technical Support Division online at any time.

Email: support@10xgenomics.com

10x Genomics 7068 Koll Center Parkway

Suite 401

Pleasanton, CA 94566 USA